Skip to main content
Premium Trial:

Request an Annual Quote

OGT Inks Deal with CCMC to Build Cancer Microarray

NEW YORK (GenomeWeb News) – Oxford Gene Technology said today it signed a license agreement with the Cancer Cytogenomics Microarray Consortium to create a whole genome, cancer-specific microarray.

The technology will incorporate probes for more than 500 cancer genes and 130 cancer-associated genomic regions from CCMC's design for hematological and solid tumors, OGT said. By accurately identifying DNA copy number changes and the loss of heterozygosity associated with different cancer types, OGT hopes to improve cancer research through the agreement.

Financial and other terms of the deal were not disclosed.

"The use of microarray technology will substantially improve the facility of cytogenetics research laboratories to identify cancer," M. Anwar Iqbal, president of CCMC, said in a statement. "The CCMC board appreciates the efforts of companies such as OGT to making the CCMC cancer array design available to the cytogenetics research community worldwide."

Formed in 2009, CCMC promotes communication and collaboration among cancer cytogenomic laboratories.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.